The company, formerly known as Axovant, is leveraging its scientific expertise and collaborations with leading gene therapy institutes to develop treatments for debilitating diseases such as Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis. Sio's flexible vector platform allows them to push the boundaries of gene therapy and liberate patients from these diseases through the transformative power of gene therapies.